Opportunity Information: Apply for RFA DA 13 008
Apply for RFA DA 13 008
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Advancing Exceptional Research on HIV/AIDS (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jun 14, 2012 and posted on Jun 14, 2012.
- Applicants must submit their applications by Dec 17, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,500,000.00 to eligible and selected applicants.
- Eligible applicants include: Special district governments Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts City or township governments Small businesses State governments Private institutions of higher education For profit organizations other than small businesses County governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Advancing Exceptional Research on HIV/AIDS (R01) funding opportunity (RFA-DA-13-008) is a National Institutes of Health (NIH) discretionary grant program designed to support highly innovative research projects at the intersection of HIV/AIDS and drug abuse. It is built around the standard NIH R01 mechanism, meaning it is intended for substantial, hypothesis-driven (or otherwise well-justified) research projects that can produce significant advances in knowledge. The central goal is to push beyond incremental progress by backing studies that can open up entirely new directions in HIV/AIDS research and, in particular, generate new ideas and approaches for preventing and treating HIV/AIDS among people who use drugs.
A key feature of this opportunity is how it positions itself relative to the NIH/NIDA Avant-Garde program. The Avant-Garde award is aimed at individuals pursuing high-risk, high-payoff science and, notably, does not require a detailed research plan. By contrast, this R01 opportunity is meant to complement that program by funding innovative projects that are still bold and potentially transformative, but that come with the more traditional expectations of an R01 submission. Applicants are required to include a detailed research plan and provide preliminary data, signaling that while the research should be inventive and capable of reshaping the field, it must also be supported by enough groundwork to demonstrate feasibility and a clear path for execution.
The scope of eligible scientific topics is intentionally broad. The announcement does not limit applicants to a single research area, which leaves room for a wide range of approaches spanning basic, translational, clinical, behavioral, prevention, and implementation-focused studies, as long as the work is clearly relevant to HIV/AIDS in the context of drug abuse. In practice, this could include projects that explore new biological mechanisms that influence HIV acquisition or progression among drug users, novel prevention strategies tailored to populations affected by substance use, innovative treatment models that address both HIV and addiction, or creative interventions to improve engagement in care and adherence. The emphasis is less on a predefined topic list and more on whether the proposed work is genuinely innovative and has the potential to create new opportunities for preventing or treating HIV/AIDS in drug-using populations.
This FOA is open to both individual investigators and collaborative research teams, reflecting NIHs intent to support either single-lab innovation or multidisciplinary efforts where the problem demands combined expertise. Eligibility is broad and includes many types of domestic U.S. organizations such as state and local governments, tribal entities, public and private institutions of higher education, nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits), and for-profit organizations including small businesses and other for-profit entities. The eligibility section also explicitly includes various mission-driven and capacity-building institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribal Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations. Importantly, non-U.S. entities (foreign institutions) are eligible to apply, and foreign components of U.S. organizations are allowed as defined under the NIH Grants Policy Statement, which expands the potential for international or cross-border research collaborations where scientifically justified.
Administratively, this opportunity is associated with CFDA number 93.279 (Drug Abuse and Addiction Research Programs). It does not require cost sharing or matching. The posting and creation date listed are June 14, 2012, with an original (and current) closing date of December 17, 2012, and an archive date of January 17, 2013. The estimated total funding amount is listed as $1,500,000, which provides a sense of the overall scale NIH anticipated committing through this announcement (though actual award sizes and the number of awards would depend on NIH decisions, application quality, and budget considerations).
For applicants seeking the full requirements, submission instructions, and any special review considerations, the official announcement was hosted through the NIH Grants Guide and is referenced via the provided additional information link. The notice also includes NIH Office of Extramural Research (OER) webmaster contact details for technical issues accessing the announcement online, which is typical for NIH postings.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
The Advancing Exceptional Research on HIV/AIDS (R01) opportunity (RFA-DA-13-008) is a National Institutes of Health (NIH) discretionary grant program supporting highly innovative research at the intersection of HIV/AIDS and drug abuse, using the standard NIH R01 mechanism.
What is the main goal of RFA-DA-13-008?
The central goal is to move beyond incremental progress by supporting studies that can open new directions in HIV/AIDS research and generate new ideas and approaches for preventing and treating HIV/AIDS among people who use drugs.
What grant mechanism does this program use?
This opportunity is built around the NIH R01 mechanism and is intended for substantial research projects that are hypothesis-driven (or otherwise well-justified) and capable of producing significant advances in knowledge.
How is this R01 opportunity different from the NIH/NIDA Avant-Garde program?
The NIH/NIDA Avant-Garde award is aimed at high-risk, high-payoff science and does not require a detailed research plan. In contrast, this R01 opportunity is meant to complement Avant-Garde by supporting bold, potentially transformative projects that still include the traditional R01 expectations, including a detailed research plan and preliminary data.
Is a detailed research plan required?
Yes. Applicants are required to include a detailed research plan, consistent with the expectations of an R01 submission.
Is preliminary data required?
Yes. The opportunity specifies that applicants must provide preliminary data, indicating that the innovative work should also be supported by groundwork demonstrating feasibility and a clear execution path.
What kinds of research topics are eligible?
The scientific scope is intentionally broad. Projects may span basic, translational, clinical, behavioral, prevention, and implementation-focused studies, as long as the work is clearly relevant to HIV/AIDS in the context of drug abuse and is genuinely innovative with potential to create new opportunities for prevention or treatment.
Does the FOA limit applicants to a narrow topic list?
No. The announcement does not restrict applicants to a single research area; the emphasis is on innovation and relevance to HIV/AIDS among people who use drugs rather than adherence to a predefined topic list.
What are examples of the kinds of projects this FOA seems intended to support?
Examples described include exploring new biological mechanisms influencing HIV acquisition or progression among drug users, developing novel prevention strategies tailored to substance-using populations, creating innovative treatment models addressing both HIV and addiction, and designing interventions to improve engagement in care and adherence.
Can both individual investigators and teams apply?
Yes. The FOA is open to both individual investigators and collaborative research teams, reflecting an intent to support single-investigator innovation as well as multidisciplinary efforts.
What organizations are eligible to apply within the United States?
Eligibility is broad and includes many domestic U.S. organization types, including state and local governments, tribal entities, public and private institutions of higher education, nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits), and for-profit organizations (including small businesses and other for-profit entities).
Are mission-driven and capacity-building institutions included as eligible organizations?
Yes. The eligibility section explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribal Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations.
Are non-U.S. (foreign) institutions allowed to apply?
Yes. Non-U.S. entities (foreign institutions) are eligible to apply.
Are foreign components of U.S. organizations allowed?
Yes. Foreign components of U.S. organizations are allowed as defined under the NIH Grants Policy Statement, enabling international or cross-border collaborations where scientifically justified.
What is the CFDA number associated with this opportunity?
This opportunity is associated with CFDA number 93.279 (Drug Abuse and Addiction Research Programs).
Does this grant require cost sharing or matching funds?
No. The opportunity does not require cost sharing or matching.
What are the key dates listed for this opportunity?
The posting and creation date is June 14, 2012. The closing date listed is December 17, 2012. The archive date is January 17, 2013.
What is the estimated total funding amount?
The estimated total funding amount listed is $1,500,000. Actual award sizes and the number of awards would depend on NIH decisions, application quality, and budget considerations.
Where can applicants find the official requirements and submission instructions?
The official announcement was hosted through the NIH Grants Guide and is referenced via the additional information link in the posting. That source contains the full requirements, submission instructions, and any special review considerations.
Who should be contacted for technical issues accessing the announcement online?
The notice includes NIH Office of Extramural Research (OER) webmaster contact details for technical issues related to accessing the announcement online.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Office of Elementary and Secondary Education (OESE) Teacher Incentive Fund (TIF) TIF General Competition CFDA Number 84.374A
Previous opportunity: Establishment of a University Partnership with the University of Gujrat, Gujrat, Pakistan
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 13 008
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 13 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Identifying Non coding RNA Targets for Early Detection of Cancer (R01) Apply for PA 12 213 Funding Number: PA 12 213 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Identifying Non coding RNA Targets for Early Detection of Cancer (R21) Apply for PA 12 214 Funding Number: PA 12 214 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R21) Apply for PA 12 220 Funding Number: PA 12 220 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Biomarkers for Early Detection of Hematopoietic Malignancies (R01) Apply for PA 12 221 Funding Number: PA 12 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cohort Studies of HIV/AIDS and Substance Use (U01) Apply for PAR 12 222 Funding Number: PAR 12 222 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R01) Apply for RFA MH 13 090 Funding Number: RFA MH 13 090 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R21) Apply for RFA MH 13 091 Funding Number: RFA MH 13 091 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Community level Approaches to Reduce HIV Infection in Highly Impacted Communities (R34) Apply for RFA MH 13 092 Funding Number: RFA MH 13 092 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Addressing Needs of Informal Caregivers of Individuals with Alzheimers Disease in the Context of Sociodemographic Factors (R01) Apply for RFA NR 13 001 Funding Number: RFA NR 13 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R01) Apply for PAR 12 228 Funding Number: PAR 12 228 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Physical activity and weight control interventions among cancer survivors Effects on biomarkers of prognosis and survival (R21) Apply for PAR 12 229 Funding Number: PAR 12 229 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Translational Research on Interventions for Adolescents in the Legal System TRIALS (U01) Apply for RFA DA 13 009 Funding Number: RFA DA 13 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PAR 12 238 Funding Number: PAR 12 238 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Clinical Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PAR 12 239 Funding Number: PAR 12 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| NCI National Clinical Trials Network Network Radiotherapy and Imaging Core Services Centers (U24) Apply for RFA CA 12 014 Funding Number: RFA CA 12 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Canadian Collaborating Clinical Trials Network (Limited Competition U10) Apply for RFA CA 12 504 Funding Number: RFA CA 12 504 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Operations Centers (U10) Apply for RFA CA 12 010 Funding Number: RFA CA 12 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Statistics and Data Management Centers (U10) Apply for RFA CA 12 011 Funding Number: RFA CA 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Group Integrated Translational Science Centers (U10) Apply for RFA CA 12 012 Funding Number: RFA CA 12 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI National Clinical Trials Network Network Lead Academic Participating Sites (U10) Apply for RFA CA 12 013 Funding Number: RFA CA 12 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 13 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.